Related Experiment Video
Updated: Oct 13, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Bioengineered angiotensin-converting-enzyme-2: a potential therapeutic option against SARS-CoV-2 infection
1Department of Chemistry, National Institute of Technology Sikkim, Ravangla Campus, Barfung Block, Ravangla Sub Division, South Sikkim, 737139, India. biplab@nitsikkim.ac.in.
Abstract:
The recombinant soluble human angiotensin-converting enzyme 2 (rshACE2) is a promising therapy against SARS-CoV-2 infection, but it has some drawbacks that reduce the success of its clinical applications. The bioengineered ACE2 (Tag-sACE2 and probiotic-ACE2) as a way may overcome its therapeutic limitations against ongoing current pandemic.
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:

